logo
Vomiting to Arrest: A 37-Year-Old's Bizarre Diagnosis

Vomiting to Arrest: A 37-Year-Old's Bizarre Diagnosis

Medscape3 days ago
A 37-year-old man with a history of Roux-en-Y gastric bypass and chronic alcohol use was found collapsed at home after a possible 48-hour period.
Shortly after initial mobilisation by emergency responders, he developed sudden cardiac arrest, with return of spontaneous circulation achieved within 2 minutes.
Following transport and hospital admission, the patient remained hypotensive and required ICU admission with mechanical ventilation.
A whole-body CT scan performed during transfer from the emergency department to the ICU revealed extensive air in the epidural space extending from the cervical to thoracic spine, along with pneumomediastinum surrounding the great vessels. No pneumothorax or free fluid was noted.
The case reported by Jérôme Dehon, MD, a resident physician in emergency medicine and critical care, and colleagues at the Université Catholique de Louvain in Brussels, Belgium, documents a rare and dramatic clinical condition.
The Patient and His History
The patient was brought to the emergency department after being found collapsed at home, with a possible 48-hour delay before the discovery.
Shortly after the initial mobilisation by the emergency responders, he experienced a sudden cardiac arrest. Cardiopulmonary resuscitation was initiated immediately, and return of spontaneous circulation was achieved within 2 minutes after a single dose of intravenous epinephrine.
Despite fluid resuscitation, the patient remained hypotensive after admission to the emergency department and was transferred to the ICU for vasopressor support and further evaluation.
He was sedated, intubated, and mechanically ventilated, and his recent postcardiac arrest status further limited the possibility of a reliable neurologic assessment.
Findings and Diagnosis
The patient's vital signs were continuously monitored. A whole-body CT scan performed during the transfer from the emergency department to the ICU revealed extensive air in the epidural space from the cervical to thoracic spine, along with pneumomediastinum surrounding the great vessels in the absence of pneumothorax or free fluid.
Collateral history from the patient's family revealed multiple episodes of severe vomiting in the days before presentation.
Given the patient's surgical history and radiologic findings, an oesophageal perforation was initially suspected. An upper endoscopy was performed but showed no evidence of a significant fistula or visible perforation.
After sedation was weaned, neurologic examination revealed no focal deficits. Transient vertical nystagmus was observed and resolved following empirical thiamine supplementation.
Although a brain MRI performed 2 weeks later showed no structural abnormalities suggestive of Wernicke encephalopathy, the clinical response supported this working diagnosis in the context of prior bariatric surgery and chronic alcohol use.
The patient's clinical status improved steadily with supportive treatment. Follow-up CT imaging showed complete resolution of both pneumomediastinum and pneumorachis.
Alveolar barotrauma secondary to repeated vomiting was considered the most likely cause, resulting in air dissection into the mediastinum and epidural space.
Discussion
Spontaneous pneumorachis, defined as the presence of air in the spinal canal without trauma or recent instrumentation, is an exceptionally rare entity. Reliable epidemiologic data on its frequency in Germany are lacking, but it is considered exceedingly rare. This case report 'serves as a reminder that while the Macklin effect offers a plausible mechanism for air dissection into the epidural space, potentially life-threatening conditions such as oesophageal rupture must always be actively excluded. The striking radiological findings initially raised concerns regarding life-threatening pathology; however, the clinical course proved benign under conservative management. The case reminds us that dramatic imaging should not overshadow clinical reasoning and that management must remain rooted in structured, evidence-based assessment,' the author concluded.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sources reveal the Trump administration's plans for cutting U.S. drug prices
Sources reveal the Trump administration's plans for cutting U.S. drug prices

Fast Company

time10 minutes ago

  • Fast Company

Sources reveal the Trump administration's plans for cutting U.S. drug prices

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt 'most favored nation' pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being 'ripped off.' The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America — the industry's main lobby group — has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. 'Prices can come down in the United States without being increased in other countries, and we can still get innovation,' she said. TOP PRIORITY Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. 'This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it,' the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. 'There's a big push from the administration to drive up prices outside the U.S.,' the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca, Bayer and Novo Nordisk signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. 'It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction,' Kaltenboeck said, 'and it doesn't make much sense for them politically.'

Big Data in Healthcare Market Trends and Forecast Report 2025-2035, with Leading Players
Big Data in Healthcare Market Trends and Forecast Report 2025-2035, with Leading Players

Associated Press

time11 minutes ago

  • Associated Press

Big Data in Healthcare Market Trends and Forecast Report 2025-2035, with Leading Players

DUBLIN--(BUSINESS WIRE)--Aug 7, 2025-- The 'Big Data in Healthcare Market Trends and Forecast Report 2025-2035: By Component, Type of Hardware, Type of Software and Service, Deployment Option, Application Area, Healthcare Vertical, End User, Economic Status, Geography and Leading Players' report has been added to offering. The global big data in healthcare market is estimated to grow from USD 78 billion in 2025, to USD 540 billion by 2035, at a CAGR of 19.20% during the forecast period, to 2035. The integration of big data analytics in the healthcare domain holds immense potential for revolutionizing the industry and unlocking lucrative business opportunities for service providers. The ability to aggregate, analyze, and derive actionable insights from vast amounts of data can enhance clinical decision-making, optimize resource allocation, and improve patient outcomes. Moreover, the integration of predictive analytics and machine learning algorithms with big data can enable early detection of diseases, personalized treatment plans, and precision medicine. This paradigm shift offers service providers the chance to develop innovative solutions, such as cloud-based platforms for real-time monitoring systems, and data-driven diagnostics. Collectively, these advancements have the potential to drastically reduce healthcare costs, enhance operational efficiency, and enable the delivery of higher quality care. As the healthcare industry continues to embrace big data analytics, the magnitude of the transformative impact and the vast business opportunities will become increasingly evident, revolutionizing the landscape for both providers and patients. Big Data in Healthcare Market: Key Insights The report delves into the current state of the big data in healthcare market and identifies potential growth opportunities within the industry. Some key findings from the report include: Big Data in Healthcare Market: Research Coverage Sample Players in the Big Data in Healthcare Market, Profiled in the Report, Include: Key Questions Answered in this Report Reasons to Buy this Report Additional Benefits For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: PROFESSIONAL SERVICES DATA MANAGEMENT HEALTH TECHNOLOGY DATA ANALYTICS OTHER HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 08/07/2025 11:52 AM/DISC: 08/07/2025 11:51 AM

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

Yahoo

time38 minutes ago

  • Yahoo

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. The presentation will be followed by a Q&A session. The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at . To receive telephone dial-in information and a unique personal access PIN, please register at Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma's website at About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma's business and activities, please visit ContactsAdam Lange (Investors)Vice President, Investor Relationsalange@ Neshat Ahmadi (Investors)Investor Relations Managerneahmadi@ Anna Krassowska, PhD (Investor and Media)Vice President, Investor Relations & Corporate Communicationsakrassowska@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store